A single ophthalmic assessment through a specialty mobile vision clinic costs $150 to $1,500, depending on complexity and staffing, a small line item compared with the $4 million average cost of a Phase 1 trial. That cost is easily offset by what it prevents: the $600,000 to $8 million per day a delayed trial can cost sponsors, and the $6,533 to $19,533 it costs to recruit or replace a single participant.
What Is a Mobile Clinic, and Why Are Sponsors Using Them in Phase 1?
A mobile clinic is a specialized vehicle that travels directly to trial participants to provide healthcare services, rather than requiring participants to travel to a fixed site. Mobile clinics reach populations traditional sites often can't: one study found more than half of mobile clinic clients are women (55%) and racial or ethnic minorities (59%). At the earliest, most budget-sensitive stage of drug development, reaching participants where they live, work, or congregate creates a more patient-first experience while reducing the execution barriers that drive up early-phase costs.
What Is a Mobile Vision Clinic Specifically?
A mobile vision clinic is a specialty version of that model, built for ophthalmic assessments. 20/20 Onsite's mobile vision clinics provide eye care services to trial participants across the country, and because the vehicle travels directly to the study site or to the participant, it reduces barriers to care without requiring participants to change their routine. Request a virtual tour to see what's on board.
How Much Does a Mobile Vision Clinic Cost?
Cost depends on the same variables that drive any clinical trial line item: study size, number of locations, number of clinical sites, and which specific tests or procedures the protocol requires. A single patient assessment typically costs $150 to $1,500, with complexity and staffing requirements accounting for most of the variation.
What Additional Benefits Come With a Mobile Vision Clinic?
- Personnel: Each mobile vision clinic comes staffed with a pre-screened, licensed optometrist and an experienced customer success team member, contributing to a Net Promoter Score of 95% or higher.
- Reach: 20/20 Onsite travels to wherever participants need us, whether that's a participant's home, a sponsor's practice, or another exam site.
- Technology and equipment: Mobile vision clinics come standard with optometry exam equipment and an Emmes-certified doctor's exam lane, and are customizable with specialty equipment such as MAIA Microperimetry, OCT, EVA, and AVOT, based on study needs.
- Pre-screening: Participants are screened before they reach the clinical site to confirm eligibility, which improves enrollment speed and reduces screen failure rates.
Adding a mobile vision clinic to a research site follows a process similar to onboarding any other vendor once the conversation with the study team starts.
Are Mobile Vision Clinics Worth the Cost for Phase 1 Trials?
Against a $4 million average Phase 1 budget, the real question isn't whether a mobile vision clinic is an added cost. It's what removing travel barriers protects against:
- Geography is the top barrier to participation. Distance to the clinical site is the main reason 60% of patients don't enroll.
- Delays are expensive and common. 80% of trials are delayed by at least a month, and each day of delay can cost sponsors $600,000, potentially up to $8 million.
- Recruitment isn't free. It costs an average of $6,533 to recruit a single patient to a clinical study.
- Screening adds up. Eligibility screening costs range from $129.15 to $336.48 per enrolled patient by study phase, with estimated annual screening costs exceeding $90,000.
- Losing a patient is more expensive than recruiting one. Replacing a patient lost to non-compliance costs an average of $19,533.
- Stress drives dropout. 38% of patients who dropped out of a clinical trial cited their visits as stressful.
A mobile clinic provides the physical point-of-need execution a hybrid study needs. Software platforms handle data management, but they don't remove the travel burden that drives most of the costs above.
How Does Mobile Execution Reach Diverse Patient Populations?
Point-of-need execution expands access to diverse patient populations while significantly reducing the operational effort sponsors and CROs spend screening participants before they arrive on-site. Because 20/20 Onsite's mobile eye exams travel on wheels, coverage extends anywhere in the continental United States. To date, our team has traveled more than 200,000 miles across 48 states, seeing hundreds of patients of all ages on behalf of pharmaceutical companies, sponsors, and CROs.
That reach shows up in the travel numbers: participants travel an average of only 12.36 miles for a 20/20 Onsite appointment, compared to an average of 41.2 miles for most clinical trials.
Pre-screening plays a direct role in that access. Rather than replacing a clinical trial site, 20/20 Onsite verifies inclusion and exclusion criteria through specialized imaging and clinical procedures before advancing a participant, giving sponsors confidence that enrolled patients are qualified before they ever reach the research site.
How Do Mobile Vision Clinics Improve Patient Experience and Retention?
No-shows are an underpriced risk in clinical trials. One study estimated that clinics and health systems lose over $150,000 per provider per year to no-shows, and the average patient no-show rate is close to 19%, rising to an estimated 25% in optometry. Applied against daily appointments, that materially affects the cost and timeline of a drug development program.
20/20 Onsite's mobile vision clinics have roughly 10% no-shows or late cancellations, well below both benchmarks, largely because reducing travel time and bringing the appointment directly to the participant remove the friction that causes most no-shows in the first place.
Participants no longer have to depend on a loved one to take time out of their day for a visit, particularly when a condition already affects their eyesight. They're also more likely to attend critical follow-up exams, since the study comes to them instead of requiring time off work or a trip to a city center. Onboard, staff can spend more time with each participant learning about their background, lifestyle, and condition, and offer breaks between exams, contributing to the same 95%+ Net Promoter Score across both the routine optometry and clinical trial sides of the business.
Small process changes, often suggested by participants themselves, have compounded into meaningful retention gains. Reordering testing so the most intense exam happens first, and adding neon tape to the aisle so participants with low vision can move around the clinic more safely, both reduced fatigue and dropout risk. As one participant put it: "Thank you all for everything you do to make things easier for our patients! They loved the experience."
How Do Mobile Vision Clinics Relieve Burden on Site Staff?
Study activation already consumes a substantial share of a trial's time and budget, including training site personnel. Working with 20/20 Onsite functions as an extension of that project management effort rather than an added layer, offsetting screen failures, protecting the trial budget, and reducing early dropout.
Pre-screen imaging and testing checks every inclusion criterion in the protocol, including age, gender, and medical history, reducing the risk that an ineligible participant advances, which is the most common cause of screen failure. Participants also arrive at the research site having already experienced a version of the testing on board the mobile vision clinic, so they know what to expect. That reduces the burden on site staff, since participants are calmer and more comfortable in the exam environment, and lowers the risk of dropout or refusal tied to unfamiliarity with the process.
If your upcoming trial requires precise ocular data capture, request a pricing and timeline review to see how specialized mobile execution protects your sample size and your path to FDA approval.
Frequently Asked Questions
How much does a mobile vision clinic cost for a Phase 1 clinical trial? A single patient assessment typically costs $150 to $1,500, depending on the complexity of the testing and the staff required. Total program cost also depends on study size, number of locations, and the specific tests a protocol requires.
Is a mobile vision clinic worth the cost compared to a traditional site visit? Usually, yes. The per-assessment cost is small compared with the $6,533 average cost of recruiting one patient, the $19,533 average cost of replacing a patient lost to non-compliance, and the $600,000 to $8 million per day that a delayed trial can cost sponsors.
What is the biggest cost driver in Phase 1 patient recruitment? Geography. Distance to the clinical site is the top-cited barrier to trial participation, cited by 60% of patients, and it compounds with recruitment costs that already average $6,533 per patient and eligibility screening costs that can exceed $90,000 annually.
How much travel burden does a mobile vision clinic actually remove? 20/20 Onsite participants travel an average of 12.36 miles per appointment, compared to a 41.2-mile average across most clinical trials. That reach comes from a fleet that has covered more than 200,000 miles across 48 states.
How does a mobile vision clinic reduce no-show rates? By bringing the appointment directly to the participant instead of requiring travel, which removes the biggest driver of no-shows. 20/20 Onsite runs at roughly 10% no-shows or late cancellations, compared to an industry average near 19% and an estimated 25% in optometry specifically.
What equipment does a mobile vision clinic bring to a Phase 1 site? 20/20 Onsite's mobile vision clinics include standard optometry exam equipment and an Emmes-certified doctor's exam lane, which is customizable with specialty equipment such as MAIA Microperimetry, OCT, EVA, and AVOT, based on protocol needs.
How does pre-screening with a mobile vision clinic reduce site burden? Pre-screening verifies all inclusion and exclusion criteria, including age, gender, and medical history, before a participant arrives at the research site. This reduces the risk of ineligible patients advancing, which is the most common cause of screen failure, and means participants arrive already familiar with the testing process.